LIXISENATIDE WINTHROP lixisenatide 10 mcg (0.05mg/mL) solution for injection injector pen Australia - English - Department of Health (Therapeutic Goods Administration)

lixisenatide winthrop lixisenatide 10 mcg (0.05mg/ml) solution for injection injector pen

sanofi-aventis australia pty ltd - lixisenatide -

CLOPIDOGREL WINTHROP clopidogrel (as hydrogen sulfate) 300 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

clopidogrel winthrop clopidogrel (as hydrogen sulfate) 300 mg tablet blister pack

sanofi-aventis australia pty ltd - clopidogrel hydrogen sulfate -

TRUVELOG insulin aspart 100 units/mL solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

truvelog insulin aspart 100 units/ml solution for injection vial

sanofi-aventis australia pty ltd - insulin aspart, quantity: 3.5 mg/ml - injection, solution - excipient ingredients: metacresol; phenol; polysorbate 20; sodium hydroxide; hydrochloric acid; water for injections; zinc chloride; sodium chloride - for the treatment of diabetes mellitus

IRBESARTAN HCT SANOFI 300/25 irbesartan 300mg and hydrochlorothiazide 25mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

irbesartan hct sanofi 300/25 irbesartan 300mg and hydrochlorothiazide 25mg film-coated tablet blister pack

sanofi-aventis australia pty ltd - hydrochlorothiazide,irbesartan -

IRBESARTAN HCT SANOFI 300/12.5 irbesartan 300 mg and hydrochlorothiazide 12.5 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

irbesartan hct sanofi 300/12.5 irbesartan 300 mg and hydrochlorothiazide 12.5 mg film-coated tablet blister pack

sanofi-aventis australia pty ltd - hydrochlorothiazide,irbesartan -

IRBESARTAN HCT SANOFI 150/12.5 irbesartan 150 mg and hydrochlorothiazide 12.5 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

irbesartan hct sanofi 150/12.5 irbesartan 150 mg and hydrochlorothiazide 12.5 mg film-coated tablet blister pack

sanofi-aventis australia pty ltd - hydrochlorothiazide,irbesartan -

PRALUENT 150 MGML Israel - English - Ministry of Health

praluent 150 mgml

sanofi israel ltd - alirocumab - solution for injection - alirocumab 150 mg / 1 ml - alirocumab - primary hypercholesterolaemia and mixed dyslipidaemiapraluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:- in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.established atherosclerotic cardiovascular diseasepraluent is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering ldl-c levels, as an adjunct to correction of other risk factors:- in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

PRALUENT 75 MGML Israel - English - Ministry of Health

praluent 75 mgml

sanofi israel ltd - alirocumab - solution for injection - alirocumab 75 mg / 1 ml - alirocumab - primary hypercholesterolaemia and mixed dyslipidaemiapraluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:- in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.established atherosclerotic cardiovascular diseasepraluent is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering ldl-c levels, as an adjunct to correction of other risk factors:- in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

CABAZITAXEL SANOFI Australia - English - Department of Health (Therapeutic Goods Administration)

cabazitaxel sanofi

sanofi-aventis australia pty ltd - cabazitaxel acetone solvate -

RESONIUM A sodium polystyrene sulfonate powder bottle Australia - English - Department of Health (Therapeutic Goods Administration)

resonium a sodium polystyrene sulfonate powder bottle

sanofi-aventis australia pty ltd - sodium polystyrene sulfonate, quantity: 999.3 mg/g - powder - excipient ingredients: saccharin; vanillin - treatment of hyperkalaemia.